

The original disclosure in Japanese was released on Feb. 14, 2024 at 15:30 (GMT+9)

Consolidated Financial Statements for the Third Quarter Ended December 31, 2023 FY2024 (April 1, 2023 - March 31, 2024) [UNAUDITED]

Company name: Takara Holdings Inc.
 Stock exchange listings: Tokyo Stock Exchange (PRIME section)
 Code number: 2531
 URL: <https://www.takara.co.jp/>
 Company representative: Mutsumi Kimura, President
 Contact: Masakazu Usami, General Manager of Public Relations & Investor Relations Dept.
 TEL: (075)241-5124

Quarterly statement filing date(as planned): February 14, 2024

- Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.
 2. Amounts are rounded down to the nearest million yen.

1. Results for the Nine months ended December 31, 2023 (April 1, 2023 – December 31, 2023)

(1) Consolidated operating results

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Nine months ended December 31, 2023		Nine months ended December 31, 2022	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	253,618	(4.5)	265,627	19.8
Operating income (loss)	17,779	(49.0)	34,885	3.9
Ordinary income (loss)	18,820	(47.0)	35,517	3.9
Net income (loss) attributable to owners of the parent	13,937	(27.0)	19,093	11.4
Net income (loss) per share (Yen)	70.55		96.58	
Fully diluted net income per share (Yen)	-		-	
Note: Comprehensive income (loss)	34,169	(25.3)	45,712	48.6

(2) Consolidated financial position

	As of December 31, 2023	As of March 31, 2023
	(Millions of yen)	(Millions of yen)
Total assets	434,742	399,174
Net assets	278,217	255,318
Equity ratio (%)	51.8	51.1
(Reference) Equity	225,284	203,951

2. Dividends

	Dividend per share (Yen)		
	Year ended March 31, 2023	Year ending March 31, 2024	Year ending March 31, 2024 (Forecast)
First quarter end	-	-	-
Third quarter end	-	-	-
Year end	38.00	-	27.00
Annual	38.00	-	27.00

Note: Correction of dividend forecast from the most recent dividend forecast: No

3. Forecast for the year ending March 31, 2024 (April 1, 2023 - March 31, 2024)

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Year ending March 31, 2024	
	(Millions of yen)	(%)
Net sales	341,000	(2.8)
Operating income (loss)	21,700	(42.8)
Ordinary income (loss)	22,500	(41.9)
Net income (loss) attributable to owners of the parent	15,000	(29.3)
Net income per share (Yen)	76.12	

Note: Correction of financial forecast from the most recent financial forecast: No

4. Others

- (1) Material changes in subsidiaries during this period
(Changes in specified subsidiaries that caused a change in the scope of consolidation): No
- (2) Accounting procedures specific to quarterly consolidated financial statements : No
- (3) Changes in accounting policies, accounting estimates and retrospective restatement
 - 1) Changes based on revisions of accounting standard: No
 - 2) Changes other than ones based on revisions of accounting standard: No
 - 3) Changes in accounting estimates: No
 - 4) Restatement: No
- (4) Number of outstanding shares (common stock)
 - 1) Number of outstanding shares at the end of each period (Treasury stocks are included):
 - As of December 31, 2023 : 199,699,743 shares
 - As of March 31, 2023 : 199,699,743 shares
 - 2) Number of treasury stocks at the end of each period:
 - As of December 31, 2023 : 3,445,673 shares
 - As of March 31, 2023 : 1,995,612 shares
 - 3) Average number of outstanding shares in each period
 - Nine months ended December 31, 2023 : 197,565,560 shares
 - Nine months ended December 31, 2022 : 197,704,143 shares

Contents of the attached document

1. Qualitative Information for the Nine Months Ended December 31, 2023	2
(1) Consolidated Financial Results	2
(2) Consolidated Financial Position	3
(3) Qualitative Information Regarding Consolidated Forecasts	4
2. Consolidated Quarterly Financial Statements and Primary Notes	5
(1) Consolidated Balance Sheets	5
(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income	7
(Consolidated Statements of Income)	7
(For the Nine Months Ended December 31, 2023 and 2022)	
(Consolidated Statements of Comprehensive Income)	8
(For the Nine Months Ended December 31, 2023 and 2022)	
(3) Notes to Consolidated Financial Statements	9
(Notes on Premise of Going Concern)	9
(Notes on Material Changes in Shareholders' Equity)	9
(Additional Information)	9
(Segment Information)	10
○ Supplement for the Consolidated Quarterly Financial Statements	

1. Qualitative Information for the Nine Months Ended December 31, 2023

(1) Consolidated Financial Results

In the nine months ended December 31, 2023, net sales decreased 4.5% year on year to ¥253,618 million, gross profit decreased 9.7% year on year to ¥84,394 million, and SG&A expenses increased 13.6% year on year to ¥66,614 million. Operating income decreased 49.0% year on year to ¥17,779 million, ordinary income decreased 47.0% year on year to ¥18,820 million, and net income attributable to owners of parent decreased 27.0% year on year to ¥13,937 million due to increases in extraordinary income as a result of sale of investment securities and decreases in net income attributable to the noncontrolling interest.

Results by business segment were as follows.

[Takara Shuzo]

In the nine months ended December 31, 2023, although sales of shochu and sake decreased year on year, sales of light-alcohol refreshers and raw alcohol increased.

As a result, net sales for Takara Shuzo increased 1.3% year on year to ¥97,619 million. Cost of sales decreased 2.0% year on year to ¥71,436 million, mainly due to a change in the sales mix, despite the continued impact of rising raw material prices. Gross profit increased 11.8% year on year to ¥26,182 million. SG&A expenses increased 5.8% year on year to ¥19,204 million due to an increase in advertising expenses, etc. Operating income was up 32.2% year on year to ¥6,978 million.

[Takara Shuzo International Group]

In the nine months ended December 31, 2023, net sales of the Overseas Alcoholic Beverages Business increased year on year mainly due to continued growth in sales of whiskey in the U.S. and U.K. as well as an increase in sales of sake. Net sales of the Japanese Food Wholesale Business in overseas markets also increased despite the impact of a slow-down in personal consumption in the U.S., Europe, etc., with the development of new business bases also contributing positively.

As a result, net sales for the Takara Shuzo International Group increased 17.7% year on year to ¥117,378 million. Despite a reduction in shipping container prices, cost of sales increased 16.2% year on year to ¥80,013 million in line with the increase in net sales. Consequently, gross profit increased 21.2% year on year to ¥37,364 million. SG&A expenses were up 27.0% year on year to ¥28,431 million, primarily due to increases in personnel expenses and rent expenses, and operating income was up 5.7% year on year to ¥8,933 million.

[Takara Bio Group]

In the nine months ended December 31, 2023, sales of testing-related products decreased due to changes in the legal categorization of COVID-19 and we also saw a slump in the life sciences research market due to the impact of the economic stagnation overseas. As a result, net sales for the Takara Bio Group decreased 50.6% year on year to ¥29,734 million. Cost of sales decreased 50.8% year on year to ¥11,692 million, mainly due to a decrease in net sales. Consequently, gross profit decreased 50.5% year on year to ¥18,041 million. SG&A expenses were up 4.0% year on year to ¥17,704 million, primarily due to increases in personnel expenses and R&D expenses. Operating income decreased 98.3% year on year to ¥336 million.

[Other]

In the nine months ended December 31, 2023, net sales of the Other segment decreased 3.1% year on year to ¥23,319 million due to decreased sales in the transportation business and the printing business. Cost of sales decreased 3.7% year on year to ¥19,963 million. Consequently, gross profit increased 0.4% year on year to ¥3,355 million. SG&A expenses increased 0.9% year on year to ¥1,432 million owing primarily to an increase in travel and transportation expenses, and operating income was down 0.0% year on year to ¥1,923 million.

Breakdown of sales results by product category

Segment	Equivalent Period of Previous Fiscal Year (From April 1, 2022, to December 31, 2022)	Period under Review (From April 1, 2023, to December 31, 2023)	YoY Comparison
Product category	Amount (Millions of yen)	Amount (Millions of yen)	(%)
Takara Shuzo			
Shochu	29,241	27,188	(7.0)
Sake	9,858	9,365	(5.0)
Light-alcohol refreshers	30,791	33,089	7.5
Other alcoholic beverages	4,198	4,228	0.7
<i>Hon Mirin</i>	7,628	7,708	1.1
Other seasonings	6,935	7,306	5.3
Raw alcohol, etc.	7,696	8,730	13.4
Total	96,350	97,619	1.3
Takara Shuzo International Group			
Overseas Alcoholic Beverages Business	12,891	15,102	17.1
Japanese Food Wholesales Business in overseas markets	88,306	104,019	17.8
Other	2,826	231	(91.8)
Elimination of intra-Group transaction on consolidation	(4,335)	(1,974)	—
Total	99,689	117,378	17.7
Takara Bio Group			
Reagents	52,469	22,989	(56.2)
Instruments	1,080	638	(40.9)
CDMO	4,669	4,369	(6.4)
Gene therapy	1,985	1,737	(12.5)
Total	60,206	29,734	(50.6)
Reported segment total	256,246	244,732	(4.5)
Other	24,069	23,319	(3.1)
Segment total	280,315	268,051	(4.4)
Sales not allocated to business segments and intersegment transactions	(14,688)	(14,433)	—
Total	265,627	253,618	(4.5)

Note: 1. Amounts include alcohol tax.

(2) Consolidated Financial Position

As of December 31, 2023, current assets were ¥248,051 million, an increase of ¥6,538 million compared with that at the end of the previous fiscal year. This was primarily due to increases in notes and accounts receivable-trade, merchandise and finished goods, and other under current assets of ¥8,813 million, ¥4,624 million, and ¥3,682 million, respectively despite a decrease in cash and deposits of ¥11,436 million. Noncurrent assets were ¥186,690 million, an increase of ¥29,029 million compared with that at the end of the previous fiscal year. This was primarily due to increases in property, plant and equipment of ¥15,858 million, mainly due to increases in buildings and structures and construction in progress, intangible assets of ¥3,932 million, and investments and other assets of ¥9,238 million due to an increase in the market valuation of investment securities.

As a result, total assets were ¥434,742 million, an increase of ¥35,567 million compared with that at the end of the previous fiscal year.

As of December 31, 2023, current liabilities were ¥82,042 million, an increase of ¥14,587 million compared with that at the end of the previous fiscal year. This was primarily due to increases in notes and accounts payable-trade of ¥2,881 million, short-term loans payable of ¥5,120 million, current portion of bonds of ¥5,000 million, and accrued alcohol tax of ¥4,219

million, despite a decrease in other under current liabilities of ¥3,519 million. Noncurrent liabilities were ¥74,482 million, a decrease of ¥1,919 million compared with that at the end of the previous fiscal year. This was primarily due to decreases in bonds payable of ¥5,000 million and long-term loans payable of ¥4,730 million, despite an increase in other under noncurrent liabilities of ¥7,860 million.

As a result, total liabilities were ¥156,524 million, an increase of ¥12,668 million compared with that at the end of the previous fiscal year.

As of December 31, 2023, total net assets were ¥278,217 million, an increase of ¥22,899 million compared with that at the end of the previous fiscal year. This was primarily due to increases in retained earnings of ¥6,424 million, valuation difference on available-for-sale securities of ¥4,003 million and foreign currency translation adjustment of ¥12,708 million due to the ongoing weakening of the yen.

As a result, the equity ratio totaled 51.8%, compared with 51.1% at the end of the previous fiscal year.

(3) Qualitative Information Regarding Consolidated Forecasts

There are no changes to the consolidated results forecasts for the fiscal year ending March 31, 2024 published in the consolidated financial statements for the second quarter ended September 30, 2023 on November 9, 2023.

2. Consolidated Quarterly Financial Statements and Primary Notes

(1) Consolidated Balance Sheets

(Millions of Yen)

	As of Mar. 31, 2023	As of Dec. 31, 2023
Assets		
Current assets		
Cash and deposits	96,820	85,383
Notes and accounts receivable-trade	69,717	78,531
Merchandise and finished goods	57,812	62,437
Work in process	1,718	1,958
Raw materials and supplies	7,372	8,055
Other	8,765	12,447
Allowance for doubtful accounts	(694)	(761)
Total current assets	241,513	248,051
Noncurrent assets		
Property, plant and equipment	88,890	104,748
Intangible assets		
Goodwill	10,668	12,850
Other	5,262	7,014
Total intangible assets	15,931	19,864
Investments and other assets		
Investment securities	30,573	35,879
Other	22,328	26,261
Allowance for doubtful accounts	(64)	(62)
Total investments and other assets	52,838	62,077
Total noncurrent assets	157,661	186,690
Total assets	399,174	434,742

(Millions of Yen)

	As of Mar. 31, 2023	As of Dec. 31, 2023
Liabilities		
Current liabilities		
Notes and accounts payable-trade	21,775	24,657
Short-term loans payable	4,919	10,039
Current portion of bonds	–	5,000
Accrued alcohol tax	5,815	10,034
Accrued expenses	6,368	7,427
Income taxes payable	2,220	3,147
Provision	3,622	2,521
Other	22,733	19,213
Total current liabilities	67,454	82,042
Noncurrent liabilities		
Bonds payable	20,000	15,000
Long-term loans payable	15,186	10,456
Net defined benefit liability	8,925	8,876
Other	32,288	40,149
Total noncurrent liabilities	76,401	74,482
Total liabilities	143,856	156,524
Net assets		
Shareholders' equity		
Capital stock	13,226	13,226
Capital surplus	1,994	1,994
Retained earnings	163,825	170,250
Treasury stock	(1,682)	(3,433)
Total shareholders' equity	177,363	182,036
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	12,974	16,977
Deferred gains or losses on hedges	286	96
Foreign currency translation adjustment	13,686	26,395
Remeasurements of defined benefit plans	(359)	(221)
Total accumulated other comprehensive income	26,588	43,247
Noncontrolling interests	51,366	52,932
Total net assets	255,318	278,217
Total liabilities and net assets	399,174	434,742

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income**(Consolidated Statements of Income)****(For the Nine Months Ended December 31, 2023 and 2022)**

(Millions of Yen)

	FY2022 (Apr. 1, 2022 – Dec. 31, 2022)	FY2023 (Apr. 1, 2023 – Dec. 31, 2023)
Net sales	265,627	253,618
Cost of sales	172,125	169,224
Gross profit	93,501	84,394
Selling, general and administrative expenses	58,615	66,614
Operating income	34,885	17,779
Nonoperating income		
Dividends income	780	927
Other	609	826
Total nonoperating income	1,389	1,754
Nonoperating expenses		
Interest expenses	235	300
Foreign exchange losses	188	–
Other	334	412
Total nonoperating expenses	757	713
Ordinary income	35,517	18,820
Extraordinary income		
Gain on sale of investment securities	136	2,670
Insurance claim income	652	–
National subsidies	63	–
Other	256	54
Total extraordinary income	1,108	2,724
Extraordinary loss		
Loss on sale and retirement of noncurrent assets	86	203
Loss on tax purpose reduction entry of noncurrent assets	63	–
Impairment losses	–	75
Other	64	–
Total extraordinary losses	214	279
Income before income taxes	36,410	21,265
Income taxes-current	9,619	7,142
Income taxes-deferred	1,026	(641)
Total income taxes	10,646	6,501
Net income	25,764	14,764
Net income attributable to the noncontrolling interest	6,670	827
Net income attributable to owners of the parent	19,093	13,937

(Consolidated Statements of Comprehensive Income)
(For the Nine Months Ended December 31, 2023 and 2022)

(Millions of Yen)

	FY2022 (Apr. 1, 2022 – Dec. 31, 2022)	FY2023 (Apr. 1, 2023 – Dec. 31, 2023)
Net income	25,764	14,764
Other comprehensive income		
Valuation difference on available-for-sale securities	(32)	4,003
Deferred gains or losses on hedges	(40)	(190)
Foreign currency translation adjustment	19,896	15,434
Remeasurements of defined benefit plans	124	157
Total other comprehensive income	19,947	19,404
Comprehensive income	45,712	34,169
(Comprehensive income attributable to)		
Comprehensive income attributable to owners of the parent	34,654	30,596
Comprehensive income attributable to noncontrolling interest	11,057	3,572

(3) Notes to Consolidated Financial Statements

(Notes on Premise of Going Concern)

No items to report.

(Notes on Material Changes in Shareholders' Equity)

No items to report.

(Additional Information)

(Acquisition and cancellation of treasury stock)

The meeting of the Company's Board of Directors held on November 9, 2023, approved the acquisition of treasury stock based on the provisions for Article 156 of the Companies Act described in Article 165 (3) of the same act and the cancellation of treasury stock based on the provision of Article 178 of the Companies Act.

1. Reasons for the acquisition and cancellation of treasury stock
The Company will acquire treasury stock in order to execute an agile capital policy that aligns with shareholder returns and the business environment. In conjunction with this, the Company will also cancel treasury stock in accordance with its policy on ownership of treasury stock.
2. Details of acquisition of treasury stock
 - (1) Classification of stock to be acquired Common stock of the Company
 - (2) Number of shares to be acquired 3.0 million shares (upper limit)
(1.52% of total number of shares issued and outstanding (excluding treasury stock))
 - (3) Total cost of acquisition ¥3.0 billion (upper limit)
 - (4) Period of acquisition November 13, 2023 to February 20, 2024
 - (5) Method of acquisition Open market purchase through the Tokyo Stock Exchange
3. Details of cancellation of treasury stock
 - (1) Classification of stock to be cancelled Common stock of the Company
 - (2) Number of shares to be cancelled Total number of shares acquired in Item 2 above
(1.50% of total number of shares issued and outstanding before cancellation (if 3.0 million shares (upper limit) are acquired))
 - (3) Scheduled cancellation date February 29, 2024

In accordance with the aforementioned meeting of the Company's Board of Directors, the Company acquired treasury stock as follows:

- (1) Classification of stock acquired Common stock of the Company
- (2) Number of shares acquired 2,447,700 shares
- (3) Total cost of acquisition ¥2,999,897,650
- (4) Period of acquisition November 13, 2023 to February 2, 2024
- (5) Method of acquisition Open market purchase through the Tokyo Stock Exchange

(Segment Information)

I. Equivalent Period of Previous Fiscal Year (From April 1, 2022 to December 31, 2022)

1. Net sales and Income (Loss) by Reported Segment

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo	Takara Shuzo International Group	Takara Bio Group	Subtotal				
Net sales								
External customers	95,685	99,541	60,203	255,431	10,195	265,627	-	265,627
Intersegment	664	147	2	814	13,873	14,688	(14,688)	-
Total	96,350	99,689	60,206	256,246	24,069	280,315	(14,688)	265,627
Segment income (loss)	5,276	8,454	19,403	33,135	1,924	35,059	(173)	34,885

Notes: 1. Other includes business segments that are not part of reported segments, such as the real estate rental business, the transportation business, and the wine import and sale business.

2. The adjustment to segment income (loss) of ¥(173) million comprises intersegment eliminations of ¥57 million and loss of the Company not allocated to business segments of ¥(231) million.

3. Segment income has been adjusted to the operating income of consolidated quarterly statements of income.

2. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment

No items to report.

II. Period under Review (From April 1, 2023, to December 31, 2023)

1. Net sales and Income (Loss) by Reported Segment

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo	Takara Shuzo International Group	Takara Bio Group	Subtotal				
Net sales								
External customers	96,963	117,061	29,733	243,757	9,860	253,618	-	253,618
Intersegment	656	317	0	974	13,458	14,433	(14,433)	-
Total	97,619	117,378	29,734	244,732	23,319	268,051	(14,433)	253,618
Segment income (loss)	6,978	8,933	336	16,248	1,923	18,171	(392)	17,779

Notes: 1. Other includes business segments that are not part of reported segments, such as the real estate rental business, the transportation business, and the wine import and sale business.

2. The adjustment to segment income (loss) of ¥(392) million comprises intersegment eliminations of ¥40 million and loss of the Company not allocated to business segments of ¥(432) million.

3. Segment income has been adjusted to the operating income of consolidated quarterly statements of income.

2. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment

Impairment loss of ¥75 million was recorded in the Takara Bio Group segment.



2024年3月期
第3四半期決算短信補足資料

Supplement for the Consolidated Financial Statements
for the Third Quarter Ended December 31, 2023

1. 宝ホールディングス(連結)
Takara Holdings Inc. -Consolidated-
グループ別要約損益計算書
Consolidated Statements of Income by Business Group (Summary)
2. 宝酒造
Takara Shuzo
要約損益計算書
Statements of Income (Summary)
3. 宝酒造インターナショナルグループ
Takara Shuzo International Group
要約損益計算書
Statements of Income (Summary)
4. タカラバイオグループ
Takara Bio Group
要約損益計算書
Statements of Income (Summary)
5. 6年間の財務サマリー(グループ別)
Six-Year Financial Summary by Business Group
6. 2024年3月期第3四半期 参考資料
Reference Data for the Third Quarter Ended December 31, 2023

宝ホールディングス株式会社
TAKARA HOLDINGS INC.

広報・IR部 [Public Relations & Investor Relations Dept.](#)

TEL 075(241)5124

FAX 075(241)5127

E-Mail ir@takara.co.jp

将来見通しに関する注意事項

この資料中の当社および当社グループの現在の計画、見通し、戦略、確信などのうち、歴史的事実でないものは、将来の業績に関する見通しであり、これらは現時点において入手可能な情報から得られた当社経営陣の判断に基づくものですが、重大なリスクや不確実性を含んでいる情報から得られた多くの仮定および考えに基づきなされたものであります。実際の業績は、さまざまな要素によりこれら予測とは大きく異なる結果となり得ることをご承知おきください。

実際の業績に影響を与える要素には、経済情勢、特に消費動向、為替レートの変動、法律・行政制度の変化、競合会社の価格・製品戦略による圧力、当社の既存製品および新製品の販売力の低下、生産中断、当社の知的所有権に対する侵害、急速な技術革新、重大な訴訟における不利な判決等がありますが、業績に影響を与える要素はこれらに限定されるものではありません。

Forward-Looking Statements

Statements in this document, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors.

Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, declines in selling power of the Company's existing and new products, disruptions to production, violations of the Company's intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.

宝ホールディングス株式会社 広報・IR部

Takara Holdings Inc. Public Relations&Investor Relations Dept.

TEL 075(241)5124 FAX 075(241)5127

E-Mail ir@takara.co.jp

1. 宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

グループ別要約損益計算書 :Consolidated Statements of Income by Business Group (Summary)

(百万円 :Millions of Yen)

	2023年3月期 第3四半期累計	2024年3月期 第3四半期累計 Apr. 1, 2023 - Dec. 31, 2023		
	実績(a) FY2023(1Q-3Q) Actual (a)	実績(b) FY2024(1Q-3Q) Actual (b)	増減(b-a) Change (b-a)	率(b/a-1) YOY% (b/a-1)
宝酒造 Takara Shuzo	96,350	97,619	1,268	1.3%
宝酒造国際グループ Takara Shuzo International Group	99,689	117,378	17,688	17.7%
タカラバイオ グループ Takara Bio Group	60,206	29,734	△ 30,471	△50.6%
その他 Other	24,069	23,319	△ 750	△3.1%
調整額 Adjustment	△ 14,688	△ 14,433	255	—
売上高 Net sales	265,627	253,618	△ 12,008	△4.5%
売上原価 Cost of sales	172,125	169,224	△ 2,901	△1.7%
売上総利益 Gross profit	93,501	84,394	△ 9,106	△9.7%
運送費、保管料 Transportation and storage	9,987	10,197	209	2.1%
広告宣伝費 Advertising	1,693	3,049	1,355	80.0%
販売促進費 Sales promotion	3,000	3,062	62	2.1%
研究開発費 Research and development	6,139	6,406	266	4.3%
管理費、その他 Other, net	37,793	43,899	6,105	16.2%
販売費及び一般管理費 SG&A expenses	58,615	66,614	7,999	13.6%
宝酒造 Takara Shuzo	5,276	6,978	1,701	32.2%
宝酒造国際グループ Takara Shuzo International Group	8,454	8,933	478	5.7%
タカラバイオ グループ Takara Bio Group	19,403	336	△ 19,066	△98.3%
その他 Other	1,924	1,923	△ 0	△0.0%
調整額 Adjustment	△ 173	△ 392	△ 218	—
営業利益(△:損失) Operating income(△:loss)	34,885	17,779	△ 17,105	△49.0%
受取利息・配当金 Interest and Dividends income	926	1,222	296	32.0%
その他営業外収益 Other, net	463	531	68	14.7%
営業外収益 Non-operating income	1,389	1,754	364	26.2%
支払利息 Interest and discounts expenses	235	300	65	27.8%
その他営業外費用 Other, net	522	412	△ 109	△21.0%
営業外費用 Non-operating expenses	757	713	△ 44	△5.9%
経常利益(△:損失) Ordinary income(△:loss)	35,517	18,820	△ 16,696	△47.0%
特別利益 Extraordinary income	1,108	2,724	1,616	145.9%
特別損失 Extraordinary loss	214	279	64	30.1%
税金等調整前四半期純利益(△:損失) Income before income taxes(△:loss)	36,410	21,265	△ 15,144	△41.6%
法人税、住民税及び事業税 Current income taxes	9,619	7,142	△ 2,477	△25.8%
法人税等調整額 Deferred income taxes	1,026	△ 641	△ 1,667	—
四半期純利益(△:損失) Net income(△:loss)	25,764	14,764	△ 10,999	△42.7%
非支配株主に帰属する四半期純利益(△:損失) Net income attributable to the noncontrolling interest(△:loss)	6,670	827	△ 5,843	△87.6%
親会社株主に帰属する四半期純利益(△:損失) Net income attributable to owners of the parent(△:loss)	19,093	13,937	△ 5,156	△27.0%
設備投資額(有形・無形) Capital expenditures	7,483	17,435	9,952	133.0%
減価償却費(有形・無形) Depreciation and Amortization	6,656	7,370	713	10.7%
のれん償却額 Amortization of goodwill	729	839	109	15.0%

営業外収益 Non-operating income	受取利息 294、受取配当金 927 など Interest income 294, Dividends income 927 etc.
営業外費用 Non-operating expenses	支払利息 300、不動産賃貸費用 74、製品等破損損失 42 など Interest and discounts expenses 300, Real estate rental costs 74, Damage loss of products 42, etc.
特別利益 Extraordinary income	投資有価証券売却益 2,670 など (前期:受取保険金 652、国庫補助金 63 など) Gain on sale of investment securities 2,670 etc. (FY2023: Insurance claim income 652, National subsidies 63 etc.)
特別損失 Extraordinary loss	固定資産売却損 203 など (前期:固定資産圧縮損 63 など) Loss on sales and retirement of non-current assets 203, etc. (FY2023: Loss on tax purpose reduction entry of non-current assets 63 etc.)

2. 宝酒造 :Takara Shuzo

要約損益計算書 :Statements of Income (Summary)

(百万円 :Millions of Yen)

	2023年3月期 第3四半期累計	2024年3月期 第3四半期累計 Apr. 1, 2023 - Dec. 31, 2023		
	実績(a) FY2023(1Q-3Q) Actual (a)	実績(b) FY2024(1Q-3Q) Actual (b)	増減(b-a) Change (b-a)	率(b/a-1) YOY% (b/a-1)
焼酎 Shochu	29,241	27,188	△ 2,052	△ 7.0%
清酒 Sake	9,858	9,365	△ 493	△ 5.0%
ソフトアルコール飲料 Light-alcohol refreshers	30,791	33,089	2,298	7.5%
その他酒類 Other liquors	4,198	4,228	30	0.7%
本みりん Hon Mirin	7,628	7,708	80	1.1%
その他調味料 Other seasonings	6,935	7,306	371	5.3%
原料用アルコール等 Raw alcohol	7,696	8,730	1,034	13.4%
売上高 Net sales	96,350	97,619	1,268	1.3%
売上原価 Cost of sales	72,925	71,436	△ 1,488	△ 2.0%
売上総利益 Gross profit	23,425	26,182	2,757	11.8%
運送費、保管料 Transportation and storage	6,148	6,014	△ 134	△ 2.2%
広告宣伝費 Advertising	1,563	2,740	1,176	75.3%
販売促進費 Sales promotion	1,737	1,707	△ 30	△ 1.7%
研究開発費 Research and development	265	279	14	5.3%
管理費、その他 Other, net	8,432	8,463	30	0.4%
販売費及び一般管理費 SG&A expenses	18,148	19,204	1,056	5.8%
営業利益(△:損失) Operating income(△:loss)	5,276	6,978	1,701	32.2%
営業外収益 Non-operating income	469	349	△ 120	△ 25.6%
営業外費用 Non-operating expenses	465	193	△ 271	△ 58.4%
経常利益(△:損失) Ordinary income(△:loss)	5,280	7,133	1,852	35.1%
特別利益 Extraordinary gain	63	23	△ 39	△ 63.3%
特別損失 Extraordinary loss	145	144	△ 0	△ 0.3%
税金等調整前四半期純利益(△:損失) Income before income taxes(△:loss)	5,198	7,011	1,813	34.9%
法人税、住民税及び事業税 Current income taxes	1,525	2,227	702	46.1%
法人税等調整額 Deferred income taxes	59	△ 85	△ 145	—
四半期純利益(△:損失) Net income(△:loss)	3,613	4,869	1,256	34.8%
設備投資額(有形・無形) Capital expenditures	1,283	1,898	615	47.9%
減価償却費(有形・無形) Depreciation and Amortization	1,810	1,865	55	3.1%

3. 宝酒造インターナショナルグループ :Takara Shuzo International Group

要約損益計算書 :Statements of Income (Summary)

(百万円 :Millions of Yen)

	2023年3月期 第3四半期累計	2024年3月期 第3四半期累計 Apr. 1, 2023 - Dec. 31, 2023		
	実績(a) FY2023(1Q-3Q) Actual (a)	実績(b) FY2024(1Q-3Q) Actual (b)	増減(b-a) Change (b-a)	率(b/a-1) YOY% (b/a-1)
海外酒類事業 Overseas Alcoholic beverages business	12,891	15,102	2,210	17.1%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	88,306	104,019	15,713	17.8%
その他 Other	2,826	231	△ 2,595	△ 91.8%
連結消去 Elimination	△ 4,335	△ 1,974	2,360	—
売上高 Net sales	99,689	117,378	17,688	17.7%
売上原価 Cost of sales	68,854	80,013	11,159	16.2%
売上総利益 Gross profit	30,835	37,364	6,529	21.2%
運送費、保管料 Transportation and storage	3,567	3,973	405	11.4%
広告宣伝費 Advertising	79	108	29	37.7%
販売促進費 Sales promotion	786	860	74	9.4%
管理費、その他 Other, net	17,946	23,488	5,541	30.9%
販売費及び一般管理費 SG&A expenses	22,380	28,431	6,051	27.0%
海外酒類事業 Overseas Alcoholic beverages business	3,392	4,014	621	18.3%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	6,305	6,734	428	6.8%
その他 Other	1,944	△ 844	△ 2,789	—
連結消去 Elimination	△ 3,187	△ 970	2,216	—
営業利益(△:損失) Operating income(△:loss)	8,454	8,933	478	5.7%
営業外収益 Non-operating income	236	324	88	37.2%
営業外費用 Non-operating expenses	136	446	309	226.3%
経常利益(△:損失) Ordinary income(△:loss)	8,554	8,811	256	3.0%
特別利益 Extraordinary gain	4	33	29	682.9%
特別損失 Extraordinary loss	1	43	42	—
税金等調整前四半期純利益(△:損失) Income before income taxes(△:loss)	8,557	8,801	243	2.9%
法人税、住民税及び事業税 Current income taxes	2,572	2,702	130	5.1%
法人税等調整額 Deferred income taxes	△ 85	△ 155	△ 69	—
四半期純利益(△:損失) Net income(△:loss)	6,070	6,253	183	3.0%
非支配株主に帰属する四半期純利益(△:損失) Net income attributable to the noncontrolling interest(△:loss)	927	743	△ 183	△ 19.8%
親会社株主に帰属する四半期純利益(△:損失) Net income attributable to owners of the parent(△:loss)	5,143	5,510	366	7.1%
設備投資額(有形・無形) Capital expenditures	3,255	5,001	1,745	53.6%
減価償却費(有形・無形) Depreciation and Amortization	1,453	1,858	405	27.9%
のれん償却額 Amortization of goodwill	291	367	75	26.0%

4. タカラバイオグループ :Takara Bio Group

要約損益計算書 :Statements of Income (Summary)

(百万円 :Millions of Yen)

	2023年3月期 第3四半期累計	2024年3月期 第3四半期累計 Apr. 1, 2023 - Dec. 31, 2023		
	実績(a) FY2023(1Q-3Q) Actual (a)	実績(b) FY2024(1Q-3Q) Actual (b)	増減(b-a) Change (b-a)	率(b/a-1) YOY% (b/a-1)
試薬 Reagents	52,469	22,989	△ 29,480	△ 56.2%
機器 Instruments	1,080	638	△ 442	△ 40.9%
受託 CDMO	4,669	4,369	△ 300	△ 6.4%
遺伝子医療 Gene Therapy	1,985	1,737	△ 247	△ 12.5%
売上高 Net sales	60,206	29,734	△ 30,471	△ 50.6%
売上原価 Cost of sales	23,771	11,692	△ 12,079	△ 50.8%
売上総利益 Gross profit	36,434	18,041	△ 18,392	△ 50.5%
運送費、保管料 Transportation and storage	506	420	△ 85	△ 16.9%
広告宣伝費 Advertising	33	49	16	47.8%
販売促進費 Sales promotion	506	527	21	4.3%
研究開発費 Research and development	5,867	6,119	251	4.3%
管理費、その他 Other, net	10,116	10,586	470	4.6%
販売費及び一般管理費 SG&A expenses	17,031	17,704	673	4.0%
営業利益(△:損失) Operating income(Δ:loss)	19,403	336	△ 19,066	△ 98.3%
営業外収益 Non-operating income	252	333	81	32.4%
営業外費用 Non-operating expenses	175	84	△ 90	△ 51.9%
経常利益(△:損失) Ordinary income(Δ:loss)	19,480	586	△ 18,893	△ 97.0%
特別利益 Extraordinary income	902	3	△ 899	△ 99.6%
特別損失 Extraordinary loss	64	88	23	36.8%
税金等調整前四半期純利益(△:損失) Income before income taxes(Δ:loss)	20,318	500	△ 19,817	△ 97.5%
法人税、住民税及び事業税 Current income taxes	4,857	722	△ 4,134	△ 85.1%
法人税等調整額 Deferred income taxes	827	△ 399	△ 1,226	—
四半期純利益(△:損失) Net income(Δ:loss)	14,633	177	△ 14,455	△ 98.8%
非支配株主に帰属する四半期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss)	38	22	△ 15	△ 39.8%
親会社株主に帰属する四半期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss)	14,595	154	△ 14,440	△ 98.9%
設備投資額(有形・無形) Capital expenditures	2,834	10,389	7,554	266.5%
減価償却費(有形・無形) Depreciation and Amortization	2,976	3,259	283	9.5%
のれん償却額 Amortization of goodwill	438	471	33	7.7%

5. 6年間の財務サマリー(グループ別) :Six-Year Financial Summary by Business Group

宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

(百万円 :Millions of Yen)

	2019年3月期 第3四半期 FY2019 (1Q-3Q)	2020年3月期 第3四半期 FY2020 (1Q-3Q)	2021年3月期 第3四半期 FY2021 (1Q-3Q)	2022年3月期 第3四半期 FY2022 (1Q-3Q)	2023年3月期 第3四半期 FY2023 (1Q-3Q)	2024年3月期 第3四半期 FY2024 (1Q-3Q)	前対比	
							Change from FY2023(1Q-3Q)	
							増減 Change	率 YOY%
売上高 Net sales	210,622	212,172	206,938	221,778	265,627	253,618	△ 12,008	△ 4.5%
売上原価 Cost of sales	127,706	130,168	120,738	137,765	172,125	169,224	△ 2,901	△ 1.7%
(売上高原価率) (Ratio to Net sales)	60.6%	61.4%	58.3%	62.1%	64.8%	66.7%	+1.9pt	3.0%
売上総利益 Gross profit	82,915	82,004	86,199	84,013	93,501	84,394	△ 9,106	△ 9.7%
販売費及び一般管理費 SG&A expenses	67,900	69,167	69,012	50,423	58,615	66,614	7,999	13.6%
(売上高販管費率) (Ratio to Net sales)	32.2%	32.6%	33.3%	22.7%	22.1%	26.3%	+4.2pt	19.0%
営業利益(△:損失) Operating income(Δ:loss)	15,015	12,836	17,186	33,589	34,885	17,779	△ 17,105	△ 49.0%
(売上高営業利益率) (Ratio to Net Sales)	7.1%	6.1%	8.3%	15.1%	13.1%	7.0%	-6.1pt	△ 46.6%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	25,131	26,071	25,368	2,765	3,000	3,062	62	2.1%
(売上高販管費率) (Ratio to Net sales)	11.9%	12.3%	12.3%	1.2%	1.1%	1.2%	+0.1pt	6.9%
研究開発費 R&D expenses	3,444	3,112	3,928	4,284	6,139	6,406	266	4.3%
(売上高研究開発費率) (Ratio to Net sales)	1.6%	1.5%	1.9%	1.9%	2.3%	2.5%	+0.2pt	9.3%
設備投資額(有形・無形) Capital expenditures	5,156	10,635	11,010	11,865	7,483	17,435	9,952	133.0%
減価償却費(有形・無形) Depreciation and Amortization	4,813	5,310	6,005	6,211	6,656	7,370	713	10.7%
のれん償却額 Amortization of goodwill	646	629	649	651	729	839	109	15.0%

*2022年3月期より、収益認識に関する会計基準等の適用に伴い、従来販売費及び一般管理費で処理していた費用の一部を売上高から控除しております。

宝酒造 :Takara Shuzo

(百万円 :Millions of Yen)

	2019年3月期 第3四半期 FY2019 (1Q-3Q)	2020年3月期 第3四半期 FY2020 (1Q-3Q)	2021年3月期 第3四半期 FY2021 (1Q-3Q)	2022年3月期 第3四半期 FY2022 (1Q-3Q)	2023年3月期 第3四半期 FY2023 (1Q-3Q)	2024年3月期 第3四半期 FY2024 (1Q-3Q)	前対比	
							Change from FY2023(1Q-3Q)	
							増減 Change	率 YOY%
売上高 Net sales	119,001	118,897	119,757	94,003	96,350	97,619	1,268	1.3%
売上原価 Cost of sales	70,919	71,578	72,111	70,195	72,925	71,436	△ 1,488	△ 2.0%
(売上高原価率) (Ratio to Net sales)	59.6%	60.2%	60.2%	74.7%	75.7%	73.2%	-2.5pt	△ 3.3%
売上総利益 Gross profit	48,081	47,318	47,646	23,807	23,425	26,182	2,757	11.8%
販売費及び一般管理費 SG&A expenses	41,397	42,334	41,501	18,670	18,148	19,204	1,056	5.8%
(売上高販管費率) (Ratio to Net sales)	34.8%	35.6%	34.7%	19.9%	18.8%	19.7%	+0.8pt	4.4%
営業利益(△:損失) Operating income(Δ:loss)	6,683	4,983	6,145	5,136	5,276	6,978	1,701	32.2%
(売上高営業利益率) (Ratio to Net sales)	5.6%	4.2%	5.1%	5.5%	5.5%	7.1%	+1.7pt	30.5%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	24,148	25,184	24,582	1,743	1,737	1,707	△ 30	△ 1.7%
(売上高販管費率) (Ratio to Net sales)	20.3%	21.2%	20.5%	1.9%	1.8%	1.7%	-0.1pt	△ 3.0%
設備投資額(有形・無形) Capital expenditures	1,019	4,616	723	801	1,283	1,898	615	47.9%
減価償却費(有形・無形) Depreciation and Amortization	1,647	1,934	2,114	1,906	1,810	1,865	55	3.1%

*2022年3月期より、収益認識に関する会計基準等の適用に伴い、従来販売費及び一般管理費で処理していた費用の一部を売上高から控除しております。

宝酒造インターナショナルグループ :Takara Shuzo International Group

(百万円 :Millions of Yen)

	2019年3月期 第3四半期 FY2019 (1Q-3Q)	2020年3月期 第3四半期 FY2020 (1Q-3Q)	2021年3月期 第3四半期 FY2021 (1Q-3Q)	2022年3月期 第3四半期 FY2022 (1Q-3Q)	2023年3月期 第3四半期 FY2023 (1Q-3Q)	2024年3月期 第3四半期 FY2024 (1Q-3Q)	前対比	
							Change from FY2023(1Q-3Q)	
							増減 Change	率 YOY%
売上高 Net sales	56,843	60,461	49,768	73,372	99,689	117,378	17,688	17.7%
売上原価 Cost of sales	40,196	43,194	34,877	49,973	68,854	80,013	11,159	16.2%
(売上高原価率) (Ratio to Net sales)	70.7%	71.4%	70.1%	68.1%	69.1%	68.2%	-0.9pt	△ 1.3%
売上総利益 Gross profit	16,647	17,266	14,891	23,399	30,835	37,364	6,529	21.2%
販売費及び一般管理費 SG&A expenses	13,416	14,953	14,253	16,761	22,380	28,431	6,051	27.0%
(売上高販管費率) (Ratio to Net sales)	23.6%	24.7%	28.6%	22.8%	22.4%	24.2%	+1.8pt	7.9%
営業利益(△:損失) Operating income(Δ:loss)	3,230	2,313	637	6,637	8,454	8,933	478	5.7%
(売上高営業利益率) (Ratio to Net sales)	5.7%	3.8%	1.3%	9.0%	8.5%	7.6%	-0.9pt	△ 10.3%
設備投資額(有形・無形) Capital expenditures	832	1,436	2,324	584	3,255	5,001	1,745	53.6%
減価償却費(有形・無形) Depreciation and Amortization	748	874	1,049	1,248	1,453	1,858	405	27.9%
のれん償却額 Amortization of goodwill	272	256	282	280	291	367	75	26.0%

タカラバイオグループ :Takara Bio Group

(百万円 :Millions of Yen)

	2019年3月期 第3四半期 FY2019 (1Q-3Q)	2020年3月期 第3四半期 FY2020 (1Q-3Q)	2021年3月期 第3四半期 FY2021 (1Q-3Q)	2022年3月期 第3四半期 FY2022 (1Q-3Q)	2023年3月期 第3四半期 FY2023 (1Q-3Q)	2024年3月期 第3四半期 FY2024 (1Q-3Q)	前対比	
							Change from FY2023(1Q-3Q)	
							増減 Change	率 YOY%
売上高 Net sales	25,888	24,558	29,549	45,659	60,206	29,734	△ 30,471	△ 50.6%
売上原価 Cost of sales	10,947	9,767	8,297	11,559	23,771	11,692	△ 12,079	△ 50.8%
(売上高原価率) (Ratio to Net sales)	42.3%	39.8%	28.1%	25.3%	39.5%	39.3%	-0.2pt	△ 0.4%
売上総利益 Gross profit	14,941	14,791	21,251	34,100	36,434	18,041	△ 18,392	△ 50.5%
販売費及び一般管理費 SG&A expenses	11,507	10,911	12,460	14,174	17,031	17,704	673	4.0%
(売上高販管費率) (Ratio to Net sales)	44.5%	44.4%	42.2%	31.0%	28.3%	59.5%	+31.3pt	110.5%
営業利益(△:損失) Operating income(Δ:loss)	3,432	3,879	8,791	19,926	19,403	336	△ 19,066	△ 98.3%
(売上高営業利益率) (Ratio to Net sales)	13.3%	15.8%	29.8%	43.6%	32.2%	1.1%	-31.1pt	△ 96.5%
研究開発費 R&D expenses	3,164	2,812	3,656	4,020	5,867	6,119	251	4.3%
(売上高研究開発費率) (Ratio to Net sales)	12.2%	11.5%	12.4%	8.8%	9.7%	20.6%	+10.8pt	111.2%
設備投資額(有形・無形) Capital expenditures	3,124	4,167	7,469	10,231	2,834	10,389	7,554	266.5%
減価償却費(有形・無形) Depreciation and Amortization	2,014	2,102	2,421	2,606	2,976	3,259	283	9.5%
のれん償却額 Amortization of goodwill	374	372	367	370	438	471	33	7.7%

6. 2024年3月期第3四半期 参考資料 :Reference Data for the Third Quarter Ended December 31, 2023

① 為替前提及び売上高に対する為替レート変動の影響 :Exchange rates and effect of change in exchange rates on net sales

◆為替前提(海外子会社P/L換算用) :Exchange rates for the income statement of oversea subsidiaries

(円 : Yen)

	2023年3月期 第3四半期累計	2024年3月期 第3四半期累計 Apr. 1, 2023 - Dec. 31, 2023	
	実績(a)	実績(b)	
	FY2023(1Q-3Q) Actual (a)	FY2024(1Q-3Q) Actual (b)	前期差(b-a) Change(b-a)
米ドル : US dollar	128.30	138.24	9.94
ポンド: Pound	160.67	172.17	11.50
ユーロ: Euro	136.05	149.76	13.71
人民元: Yuan	19.38	19.62	0.24
100ウォン: 100 Won	10.09	10.62	0.53
インドルピー: Rupee	1.66	1.68	0.02
オーストラリアドル :Australian dollar	90.55	92.37	1.82

◆売上高に対する為替レート変動の影響額 :Effect of change in exchange rates on net sales

(百万円 :Millions of Yen)

	対前期 Change from FY2023(1Q-3Q)
宝ホールディングス 計 Net sales of Takara Holdings Inc. -Consolidated-	9,692
宝酒造インターナショナルグループ 計 Net sales of Takara Shuzo International Group	8,527
海外酒類事業 Overseas Alcoholic beverages business	987
海外日本食材卸事業 Japanese food wholesale business in overseas markets	7,680
その他および調整額 Other / Adjustment	△ 140
タカラバイオグループ 計 Net sales of Takara Bio Group	1,164
試薬 Reagents	1,017
機器 Instruments	21
受託 CDMO	6
遺伝子医療 Gene Therapy	119

② 海外売上高比率の推移 :Change in overseas sales ratio

(百万円 :Millions of Yen)

	2023年3月期第3四半期 実績 FY2023(1Q-3Q) Actual			2024年3月期第3四半期 実績 FY2024(1Q-3Q) Actual		
	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio
宝酒造 Takara Shuzo	96,350	—	—	97,619	—	—
宝酒造インターナショナルグループ Takara Shuzo International Group	99,689	99,288	99.6%	117,378	116,690	99.4%
タカラバイオグループ Takara Bio Group	60,206	24,274	40.3%	29,734	20,079	67.5%
その他および調整額 Other / Adjustment	9,380	—	—	8,886	—	—
宝ホールディングス(連結) Takara Holdings Inc. -Consolidated-	265,627	123,563	46.5%	253,618	136,769	53.9%

③ 宝酒造インターナショナルグループおよびタカラバイオグループの主要子会社の業績 :Financial Forecast of major subsidiaries

		2023年3月期第3四半期 実績 FY2023(1Q-3Q) Actual		2024年3月期第3四半期 実績 FY2024(1Q-3Q) Actual	
		売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
米国宝酒造 Takara Sake USA Inc.	千 US ドル :Thousands of US dollar 百 万 円 :Millions of Yen	34,258 4,395	4,376 561	33,803 4,672	3,868 534
宝酒造食品 (中国) Takara Shuzo Foods Co.,Ltd. (China)	千 元 :Thousands of Yuan 百 万 円 :Millions of Yen	29,703 575	Δ 2,502 Δ 48	34,234 671	Δ 1,823 Δ 35
トマーチン (英国) The Tomatin Distillery Co.,Ltd (U.K.)	千 ポ ン ド :Thousands of Pound 百 万 円 :Millions of Yen	21,930 3,523	7,491 1,203	22,689 3,906	6,723 1,157
エイジ・インターナショナル (米国) AGE INTERNATIONAL,INC. (U.S.)	千 US ドル :Thousands of US dollar 百 万 円 :Millions of Yen	30,506 3,913	14,629 1,876	38,371 5,304	17,756 2,454
フーデックス7社連結 (欧州) FOODEX Group (Europe)	千 ユ ー ロ :Thousands of Euro 百 万 円 :Millions of Yen	135,665 18,457	11,921 1,621	133,213 19,949	6,695 1,002
コムポート・ケタフーズ (欧州) Cominport Distribución S.L., Keta Foods, Lda (Europe)	千 ユ ー ロ :Thousands of Euro 百 万 円 :Millions of Yen	65,931 8,970	6,253 850	74,671 11,182	8,648 1,295
タザキフーズ (英国) TAZAKI FOODS LTD. (U.K.)	千 ポ ン ド :Thousands of Pound 百 万 円 :Millions of Yen	50,799 8,161	1,292 207	56,289 9,691	3,234 556
ミュールチャルトレーディング (米国) Mutual Trading Co., Inc.	千 US ドル :Thousands of US dollar 百 万 円 :Millions of Yen	371,146 47,618	23,041 2,956	417,856 57,764	22,125 3,058
ニッポンフード (豪州) Nippon Food Supplies Company Pty Ltd (Austraria)	千 AUS ドル :Thousands of Australian dollar 百 万 円 :Millions of Yen	46,045 4,169	3,537 320	49,514 4,573	3,267 301
東京共同貿易 Tokyo Mutual Trading Co., Ltd.	百 万 円 :Millions of Yen	10,445	610	10,583	595
タカラバイオヨーロッパS.A.S. 連結 Takara Bio Europe S.A.S. Consolidated	千 ユ ー ロ :Thousands of Euro 百 万 円 :Millions of Yen	24,958 3,395	1,369 186	22,422 3,358	Δ 1,879 Δ 281
宝生物工程(大連) Takara Biotechnology (Dalian) Co.,Ltd.	千 元 :Thousands of Yuan 百 万 円 :Millions of Yen	221,834 4,299	67,602 1,310	146,920 2,882	10,451 205
宝日医生物技術(北京) Takara Biomedical Technology(Beijing) Co., Ltd.	千 元 :Thousands of Yuan 百 万 円 :Millions of Yen	410,326 7,952	64,743 1,254	241,333 4,734	19,662 385
タカラコアバイオメディカル Takara Korea Biomedical Inc.	百 万 ウ ォ ン :Millions of Won 百 万 円 :Millions of Yen	10,722 1,081	1,703 171	10,298 1,093	1,672 177
タカラバイオDSSインド DSS Takara Bio India Private Limited	千 イ ン ド ル ビ ー :Thousands of Rupee 百 万 円 :Millions of Yen	533,116 884	53,578 88	293,969 493	26,611 44
タカラバイオUSA Takara Bio USA, Inc.	千 US ドル :Thousands of US dollar 百 万 円 :Millions of Yen	104,372 13,391	20,702 2,656	86,017 11,891	3,806 526

④ 宝酒造 売上総利益増減要因 :Factors of change in Gross profit of Takara Shuzo

(百万円 :Millions of Yen)

	対前期増減 Change from FY2023(1Q-3Q)		
	増減計 Total Change	売上差 Change in quantities	構成差 Change in sales composition
売上総利益 計 Gross profit	+2,757	+308	+2,449
(参考)原価コストダウン Reference :Cost reduction	Δ 2,113	※上記構成差を含む *Included in change in sales composition	

※利益の増加要因を「+」、減少要因を「Δ」で表示

*An increasing factor and a decreasing factor on profit are shown 「+」 and 「Δ」, respectively

⑤ 宝ホールディングス(連結)要約損益計算書(p.1)における「その他」の内訳

Breakdown of "Other" segment in the Consolidated Statements of Income of Takara Holdings Inc. (Summary) (p.1)

(百万円 :Millions of Yen)

	2023年3月期第3四半期 実績 FY2023(1Q-3Q) Actual		2024年3月期第3四半期 実績 FY2024(1Q-3Q) Actual	
	売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
ワイン輸入販売事業 Import and sale of wine	4,249	847	4,199	915
物流事業 Transportation	10,534	507	10,151	454
宝ホールディングス(不動産事業) Takara Holdings (Real estate business)	375	310	379	314
その他 Other	8,910	258	8,589	238
「その他」計 Total "Other"	24,069	1,924	23,319	1,923